Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jan 2018

Overman M J, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic T R, Azad N, Kopetz S

Abstract excerpt

Background: Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins
Share to CpG Islands

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Intestine, Small

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Paclitaxel

Share to Poly-ADP-Ribose Binding Proteins

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29069279
DOI: 10.1093/annonc/mdx688
PMCID: PMC5834085

Genes

APC
CHFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.PMID 29069279Read ↗

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.Semantic proximity Read ↗

Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial.Semantic proximity Read ↗

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.Semantic proximity Read ↗

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.Semantic proximity Read ↗

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.Semantic proximity Read ↗

CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer.Semantic proximity Read ↗

The CpG Island Methylator Phenotype Status in Synchronous and Solitary Primary Colorectal Cancers: Prognosis and Effective Therapeutic Drug Prediction.Semantic proximity Read ↗

Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report.Semantic proximity Read ↗

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.